Research programme: allergic respiratory disease therapeutics - Protectimmun
Latest Information Update: 05 Aug 2016
At a glance
- Originator Protectimmun
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Allergic asthma
Most Recent Events
- 05 Aug 2016 Preclinical trials in Allergic asthma in Germany (unspecified route)